International Journal of Advanced Psychiatric Nursing
February 1, 2026
Mouni Blessina Variganji, Vidyani Devi
Background: Mindfulness-based interventions (MBIs) have demonstrated consistent efficacy in reducing anxiety and depression. However, the underlying psychological mechanisms explaining these effects particularly emotional regulation and resilience remain underexplored in Indian clinical populations. Objective: This study investigates the mediating roles of emotional regulation and resilience in...
European Child & Adolescent Psychiatry
February 2026
Konstantinos N Fountoulakis, Paraskevi Tatsiopoulou, Athanasios Saitis et al.
Ketamine and esketamine have been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior in adults. The current paper aimed to systematically review the available data on their efficacy in children and adolescents. The MEDLINE was searched with the keyword 'esketamine' on July 5th, 2024 (by following the PRISMA statement)....
International Journal of Advanced Psychiatric Nursing
February 1, 2026
Mouni Blessina Variganji, Vidyani Devi
Background: Anxiety and depression are leading causes of disability in India, with nearly 15% of adults experiencing some form of mental morbidity. Despite existing pharmacological and psychotherapeutic treatments, accessibility, affordability, and cultural barriers persist. Mindfulness-Based Interventions (MBIs), adapted from the Mindfulness-Based Stress Reduction (MBSR) model, offer a...
Annals of the New York Academy of Sciences
February 1, 2026
Shashank Ghai, Pawel Odyniec, Ishan Ghai
The global mental health crisis has escalated to unprecedented levels, with stress, anxiety, and depression posing major public health concerns. Conventional interventions have shown limited success in addressing these multifaceted issues, prompting researchers to explore alternative solutions. Yoga Nidra (YN), a meditative practice, has gained momentum over the past decade as a potential...
Indian Journal of Psychiatry
February 1, 2026
Mahak Aggarwal, Jawahar Singh, Khushpreet Kaur et al.
Major depressive disorder and co-morbid substance use disorder represent a challenging dual diagnosis, characterized by persistent anhedonia, high relapse rates, and poor response to conventional antidepressants. The dextromethorphan-bupropion combination with synergistic glutamatergic and dopaminergic mechanisms provides a new treatment option. We present three male patients with alcohol or...
Journal of Affective Disorders
February 1, 2026
Kayla M Teopiz, Sabrina Wong, Gia Han Le et al.
Convergent evidence suggests that disrupted reward processing may be associated with observed alterations in frontostriatal activity in persons with major depressive disorder (MDD). Replicated evidence suggests that glutamatergic modulators may benefit persons experiencing disrupted reward function compared to healthy controls (HC). Herein, we systematically reviewed functional magnetic...
CNS Drugs
February 1, 2026
Matheus G Marques, Liliana Patarroyo-Rodriguez, Balwinder Singh
Bipolar disorder affects approximately 40 million individuals worldwide, with depression being the most prominent phase of the illness. Owing to limited treatment options, bipolar depression remains a major public health concern, often causing significant functional impairment and increased suicide risk. Current therapies frequently lack rapid effectiveness, highlighting the need for novel...
Clinical Psychology Review
February 1, 2026
Liucan Xu, Simon B. Goldberg, Lin Zhang et al.
1 citation
Second-generation mindfulness-based interventions (SG-MBIs), which integrate ethical and moral practices, have emerged as promising treatments for depressive and anxiety symptoms. This meta-analysis aims to evaluate the effectiveness of SG-MBIs in reducing depression and anxiety among adults. We conducted a meta-analysis of randomized controlled trials (RCTs) including adults from clinical...
Substance Use & Misuse
February 1, 2026
Kai-Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt et al.
Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...
Mental Health Clinician
February 1, 2026
Parna Haghparast, Busuyi Olotu, Carol Yuan
MDD can affect anyone regardless of age, and it often starts during late teens or early adulthood. Although some patients with MDD have an adequate response to medications, only approximately 50% respond to the first treatment, and approximately 30% do not achieve remission despite multiple interventions. Several strategies exist for treating patients who have failed multiple first-line agents,...